Onconova TherapeuticsInc. (NASDAQ:ONTX) traded at $0.66 at close of the session on Tuesday, May 04, made a downturn move of -7.85% on its previous day’s price.
Looking at the stock we see that its previous close was $0.72 and the beta (5Y monthly) reads 1.6 with the day’s price range being $0.6543 – 0.7300. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, ONTX has a high of $1.93 and a low of $0.19. The company’s stock has gained about -30.13% over that past 30 days.
Onconova TherapeuticsInc. has a market cap of $158.38 Million and is expected to release its quarterly earnings report on March 11, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ONTX stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.03, with the EPS growth for the year raised at -$0.1 for 2021 and -$0.12 for next year. These figures represent -0.29% and 0.2% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $60Million, with a low of $60Million and a high of $60Million. The median projection represents growth adding up to -60% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $130Million, or -43.7% down from figures reported last year.
On the other hand, looking at the outlook for the ONTX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of Hold.
Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Onconova TherapeuticsInc. (ONTX) stock as a Hold, while 1 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the ONTX stock currently stands at 0, and the current price level is -9.95% off its SMA20 and -33.09% from its 50-day simple moving average. The RSI (14) is pointing at 38.78 while the volatility over the past week is 8.44% and jumps to 9.62% over the past one month. The beta value is 1.6, while the average true range (ATR) is currently pointing at 0.08. The average price target for the stock over the next 12 months is $2.1, with the estimates having a low of $2.1 and a high of $2.1. These price ends are 218.18% and +218.18% off the current price level respectively, although investors could be excited at the prospect of a +218.18% if the ONTX share price touches on the median price of $2.1.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Let’s briefly compare Onconova TherapeuticsInc. (ONTX) stock to its peers. We find that current price change of -7.85% and +115.61% over the past 12 months for ONTX competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 1.28% in the last trading session and was +37.41% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has climbed 0.84% previous session, but was -5.5% down over the past year, while Catalent Inc (CTLT) was also down -7.85% in the last session, while its price remained in the green at 115.61% over the same period. Onconova TherapeuticsInc. has a P/E ratio of 0 compared to Zoetis Inc Cl A’s 51.19 and Takeda Pharmaceutical Co. Ltd’s 31.95. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 0.27% and 0.7%, respectively, at close of the trading.
Coming back to Onconova TherapeuticsInc. (NASDAQ:ONTX), we note that the average 3-month trading volume was 50.24 Million, while that of the preceding 10-day period stands at 8.46 Million. Current shares outstanding are 236.61 Million.
According to data from Thomson Reuters, insiders hold 0.53% of the company’s shares while institutions hold 15.08%. The data shows that short shares as of April 14, 2021, stood at 6.02 Million at a short ratio of 0.43. This represents a 2.54% short interest in shares outstanding on April 14, 2021. Shares short dropped in April from the previous month at 11.62 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +42.34% up in year-to-date price movement.